Address: Via Valosa di Sopra, 9 ,20900 – Monza – Italy
Tel: +39.039.7390.1
Web: http://www.rotta.com/en/index.html
The group started its activities in 1961, when Luigi Rovati, founded in Monza (Italy) the Rotta Research
Laboratorium. Since then the company has always been focusing on research, innovation, development
and global distribution of new, mainly pharmaceutical products and extended the activities on para-pharmaceutical products later on.
The group’s traditional research fields in the gastrointestinal/digestive area and in the osteo-articular area have been extended, through intensive activity, to include the fields of hormone replacement therapy/women’s health/gynaecology and, more recently, the cardiovascular, respiratory tract and central nervous system areas.
In 2000, with the acquisition of Saugella and Babygella brands, Rottapharm entered the personal care sector, gaining the leadership in the market of personal hygiene products sold in pharmacies. At the same time, Rottapharm developed a nutraceutical product line, based on natural ingredients.
With the acquisition of Biochimici PSN in 2005, Rottapharm gained the leadership in the Personal Care through Pharmacy Channel, and the 6th position in Europe.
The groups headquarter and research center is in Monza, Italy with four manufacturing sites in Europe: Confienza (Italy), Dublin (Ireland), Wiehl (Germany)
and Lisbon (Portugal).
To date the intense research activity has generated over 4000 molecular hits, about 300 patents and 19 new drugs. Several new chemical entities are at an
advanced stage of research. Rottapharm produces and distributes well-known brands such as Dona, Ananase, Epinitril, Estromineral, Saugella and
Babygella.
With the acquisition of 100% of the global German pharmaceutical company Madaus Pharma on August 2007, the Rottapharm Group, has become one of the leading companies focused on the development and distribution of natural pharmaceuticals.
This acquisition is the most important M&A operation ever completed by an Italian pharmaceutical company.
In 2006 Rottapharm reported revenues of 286 million euro and an EBITDA of 89 million euro (EBITDA margin equal to 31%). With the acquisition of Madaus Pharma, the new group has closed the fiscal year 2007 with consolidated revenues of around 550 million euro, and an EBITDA of 126 million euro.
Mr. Garrahy, can you please begin by introducing yourself and this production facility to our readers? I joined Rottapharm in 1998, when the organization decided to establish its Dublin production…
Maurizio Marchesini, CEO of Marchesini Group, discusses the challenges of competing in a very dynamic packaging machinery industry, where their business is differentiated through flexibility and integral service offerings. Further,…
Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and…
Paolo Marcucci, President and CEO of Kedrion Biopharma, talks about the factors behind the company’s incredible growth and its commitment to doubling exports to the US. Furthermore, he talks about…
Shire Italy’s Francesco Scopesi discusses innovative medicine, rare diseases, growth drivers, global strategy, and the new trend of home care. Shire is today one of the leading biotechs delivering innovative…
Long renowned for dancing to a different tune, Italy’s eccentric, but more often than not, enlightened and high performance pharma, healthcare and life sciences community may at last be about…
Doppel has been selected as the nucleus for significant investments in the CDMO industry by PE firm Trilantic Capital Partners, according to recently hired CEO Giuseppe Cassisi, who shares the organization’s plans to…
Sergio Liberatore discusses IMS Health Italy’s evolution after the acquisition of Cegedim’s CRM and strategic data businesses and how IMS is paving the way for pharma companies to become more patient-centric. When we last…
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian…
Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the…
GE Healthcare Italy’s Marco Campione discusses patient access to innovation, synergies between pharma and medtech in companion diagnostics, and partnering with the Italian healthcare system. You have been working at…
Having successfully accomplished a four-year turnaround exercise and with a fresh capital injection from a leading Italian PE firm, SIFI executive chairman Fabrizio Chines has ambitious growth objectives for the…
See our Cookie Privacy Policy Here
